AMEERA-4 is a phase 2 “window of opportunity” study that tests two dose levels of amcenestrant versus letrozole given for 14 days to patients with ER+, HER2- localized BC who are candidates for breast-conserving therapy or upfront mastectomy. The gene discussed is ERBB2; the disease is breast cancer.